Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder caused by SERPINA1 gene mutations, leading to conditions like pulmonary emphysema and liver dysfunction. The AATD market is in its ...

Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.

- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam ...

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- The "Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's ...

Austin, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Alpha-1 Antitrypsin Deficiency Market Size & Growth Analysis: According to SNS Insider, The Alpha-1 Antitrypsin Deficiency Market was valued at USD ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Augmentation therapy increased survival in patients with ...

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver ...

CAMBRIDGE, Mass., Dec. 12, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting the first demonstration of physiological protein levels of human alpha-1 antitrypsin (AAT) ...

Dublin, Sept. 14, 2020 (GLOBE NEWSWIRE) -- The "Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's ...

Wave Life Sciences (NASDAQ:WVE) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 ...